Evidence map›Paper›PMID 30964270›Full record

ArticleACS nano2019

Polysaccharide Nanoparticles Can Efficiently Modulate the Immune Response against an HIV Peptide Antigen.

Tamara G Dacoba, Robert W Omange, Hongzhao Li, José Crecente-Campo, Ma Luo, Maria Jose Alonso

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Trends in nano-platforms for the treatment of viral infectious diseases.The Korean journal of chemical engineering · 2023
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Tamara G DacobaCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela , Santiago de Compostela 15782 , Spain.
Robert W OmangeDepartment of Medical Microbiology and Infectious Diseases , University of Manitoba , Winnipeg , MB R3E 0J9 , Canada.
Hongzhao LiDepartment of Medical Microbiology and Infectious Diseases , University of Manitoba , Winnipeg , MB R3E 0J9 , Canada.
José Crecente-CampoCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela , Santiago de Compostela 15782 , Spain.
Ma LuoDepartment of Medical Microbiology and Infectious Diseases , University of Manitoba , Winnipeg , MB R3E 0J9 , Canada.
Maria Jose AlonsoCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela , Santiago de Compostela 15782 , Spain.ORCID 0000-0001-7187-9567
Universidade de Santiago de Compostela · ESUniversity of Manitoba · CAPublic Health Agency of Canada · CA

Funding

A Novel HIV-1 Vaccine Targeting the 12 protease Cleavage SitesR01AI111805 · NIAID · UNIVERSITY OF MANITOBA · PI LUO, MA, PLUMMER, FRANK A · 2014 to 2017
$2.8M
NIAID NIH HHS R01 AI111805
6 · The paper itself

Abstract

The development of an effective HIV vaccine continues to be a major health challenge since, so far, only the RV144 trial has demonstrated a modest clinical efficacy. Recently, the targeting of the 12 highly conserved protease cleavage sites (PCS1-12) has been presented as a strategy seeking to hamper the maturation and infectivity of HIV. To pursue this line of research, and because peptide antigens have low immunogenicity, we have included these peptides in engineered nanoparticles, aiming at overcoming this limitation. More specifically, we investigated whether the covalent attachment of a PCS peptide (PCS5) to polysaccharide-based nanoparticles, and their coadministration with polyinosinic:polycytidylic acid (poly(I:C)), improved the generated immune response. To this end, PCS5 was first conjugated to two different polysaccharides (chitosan and hyaluronic acid) through either a stable or a cleavable bond and then associated with an oppositely charged polymer (dextran sulfate and chitosan) and poly(I:C) to form the nanoparticles. Nanoparticles associating PCS5 by ionic interactions were used in this study as the control formulation. In vivo, all nanosystems elicited high anti-PCS5 antibodies. Nanoparticles containing PCS5 conjugated and poly(I:C) seemed to induce the strongest activation of antigen-presenting cells. Interestingly, T cell activation presented different kinetics depending on the prototype. These findings show that both the nanoparticle composition and the conjugation of the HIV peptide antigen may play an important role in the generation of humoral and cellular responses.

Indexed as

Amino Acid SequenceAnimalsAntibody FormationAntigens, ViralChitosanFemaleFreeze DryingHIVHyaluronic AcidLymphocyte ActivationMacrophagesMice, Inbred BALB CMonocytesNanoparticlesPeptidesPoly I-CAntigens, ViralChitosanHyaluronic AcidPeptidesPoly I-CPolysaccharidesantigen encapsulationHIV vaccinenanoparticlenanovaccinepeptide antigenpoly(I:C)polysaccharide

Identifiers

PMID30964270
PMCPMC6607401
OpenAlexW2939630748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.